{"filing":{"accession_number":"0001104659-26-071011","cik":"0001710072","ticker":"EWTX","company_name":"Edgewise Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"tm2616953d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710072/000110465926071011/tm2616953d1_8k.htm"},"events":[{"id":6422,"run_id":5625,"accession_number":"0001104659-26-071011","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from the Annual Meeting held on June 4, 2026, covering three proposals: election of three Class II Directors (Laura Brege, Badreddin Edris, and Jonathan Root), ratification of KPMG LLP as independent auditor, and advisory vote on named executive officer compensation. The filing directly matches Item 5.07 requirements and presents final vote tallies for each proposal.","company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","filing_date":"2026-06-05","form":"8-K","submitted_at":null,"items":[{"id":4886,"accession_number":"0001104659-26-071011","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the Annual Meeting held on June 4, 2026, covering three proposals: election of three Class II Directors (Laura Brege, Badreddin Edris, and Jonathan Root), ratification of KPMG LLP as independent auditor, and advisory vote on named executive officer compensation. The filing directly matches Item 5.07 requirements and presents final vote tallies for each proposal.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:35:05.663217+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4886,"accession_number":"0001104659-26-071011","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the Annual Meeting held on June 4, 2026, covering three proposals: election of three Class II Directors (Laura Brege, Badreddin Edris, and Jonathan Root), ratification of KPMG LLP as independent auditor, and advisory vote on named executive officer compensation. The filing directly matches Item 5.07 requirements and presents final vote tallies for each proposal.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:35:05.663217+00:00","company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","filing_date":"2026-06-05"}]}